

Special Issue

DYRK Protein Kinases: Function and Inhibition

Message from the Guest Editor

DYRKs (dual-specificity tyrosine-regulated kinases) are an evolutionarily conserved family of protein kinases. The substrate proteins phosphorylated by DYRKs are very diverse and are involved in the regulation of various intracellular events. DYRKs have attracted considerable attention as drug targets in several diseases. DYRK1A has been identified as a drug target in Alzheimer's disease and Down syndrome. In addition, other DYRK protein kinases are also attracting attention as drug targets in cancer and other diseases. This Special Issue reviews and reports on the involvement of DYRK family kinases in various diseases and the current status of the research on and development of inhibitors for disease treatment.

Guest Editor

Prof. Dr. Isao Kii

School of Science and Technology, Shinshu University, Matsumoto, Japan

Deadline for manuscript submissions

30 November 2025



Molecules

an Open Access Journal
by MDPI

Impact Factor 4.6
CiteScore 8.6
Indexed in PubMed



mdpi.com/si/235066

Molecules
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
molecules@mdpi.com

[mdpi.com/journal/
molecules](https://mdpi.com/journal/molecules)





Molecules

an Open Access Journal
by MDPI

Impact Factor 4.6
CiteScore 8.6
Indexed in PubMed



[mdpi.com/journal/
molecules](https://mdpi.com/journal/molecules)



About the Journal

Message from the Editor-in-Chief

As the premier open access journal dedicated to experimental organic chemistry, and now in its 25th year of publication, the papers published in *Molecules* span from classical synthetic methodology to natural product isolation and characterization, as well as physicochemical studies and the applications of these molecules as pharmaceuticals, catalysts and novel materials. Pushing the boundaries of the discipline, we invite papers on multidisciplinary topics bridging biochemistry, biophysics and materials science, as well as timely reviews and topical issues on cutting edge fields in all these areas.

Editor-in-Chief

Prof. Dr. Thomas J. Schmidt

Institute of Pharmaceutical Biology and Phytochemistry, University of Münster, Corrensstrasse 48, D-48149 Münster, Germany

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, MEDLINE, PMC, Reaxys, CaPlus / SciFinder, MarinLit, AGRIS, and other databases.

Journal Rank:

JCR - Q2 (Biochemistry and Molecular Biology) / CiteScore - Q1 (Organic Chemistry)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 16.1 days after submission; acceptance to publication is undertaken in 2.6 days (median values for papers published in this journal in the first half of 2025).